Compare ALSN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | ARWR |
|---|---|---|
| Founded | 1915 | 2003 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.4B |
| IPO Year | 2011 | 2009 |
| Metric | ALSN | ARWR |
|---|---|---|
| Price | $110.27 | $62.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $140.45 | $107.23 |
| AVG Volume (30 Days) | 676.1K | ★ 2.0M |
| Earning Date | 10-28-2026 | 11-24-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $3,010,000,000.00 | $16,142,321.00 |
| Revenue This Year | $97.32 | N/A |
| Revenue Next Year | $4.13 | N/A |
| P/E Ratio | $31.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.01 | $34.61 |
| 52 Week High | $137.62 | $95.49 |
| Indicator | ALSN | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 32.23 |
| Support Level | $97.64 | $60.87 |
| Resistance Level | $113.31 | $66.37 |
| Average True Range (ATR) | 3.65 | 2.41 |
| MACD | -0.41 | 0.03 |
| Stochastic Oscillator | 32.89 | 25.44 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.